Clinical Trials Sponsored by Protein Sciences Corporation

Total 597 results

Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States
Protein Sciences Corporation

Completed

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

Influenza

United States
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
Protein Sciences Corporation

Completed

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Influenza

United States
Protein Sciences Corporation

Completed

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PSC25)

Influenza

United States
Protein Sciences Corporation

Completed

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Influenza

United States
Protein Sciences Corporation

Completed

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Influenza

United States
Sanofi
Protein Sciences Corporation

Completed

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Influenza

United States
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
Protein Sciences Corporation
Syneos Health; Department of Health and Human Services

Completed

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Influenza

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; MicroGeneSys Inc (nka Protein Sciences Corporation)

Completed

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

HIV Infections

United States, Puerto Rico
Exact Sciences Corporation

Completed

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

Colorectal Cancer

United States
Exact Sciences Corporation

Completed

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Kidney Cancer | Stomach Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Liver Cancer | Renal Pelvis Cancer | Uterine Cancer

United States
Exact Sciences Corporation

Completed

Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.

Colo-rectal Cancer

United States
Exact Sciences Corporation

Completed

Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program (2016-11)

Healthy

United States
Exact Sciences Corporation

Terminated

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies

Hematologic Malignancy

United States
Exact Sciences Corporation

Terminated

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

Digestive System Diseases | Colonic Diseases | Colorectal Neoplasms | Colorectal Cancer

United States, Canada
Exact Sciences Corporation

Completed

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

Digestive System Diseases | Colonic Diseases | Colorectal Neoplasms | Colorectal Cancer | Inflammatory Bowel Disease

United States, Canada
Exact Sciences Corporation

Recruiting

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Colorectal Cancer

United States, Canada
Exact Sciences Corporation

Completed

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

Colorectal Cancer

United States
Exact Sciences Corporation

Completed

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

Colorectal Cancer

United States
Exact Sciences Corporation

Completed

Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer

Lung Cancer (Diagnosis)

United States
Exact Sciences Corporation

Terminated

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Melanoma

United States
Exact Sciences Corporation

Completed

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

Colorectal Cancer

United States
Exact Sciences Corporation

Completed

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease (OCEANIA)

Colorectal Neoplasms | Colorectal Cancer | Inflammatory Bowel Disease (IBD) | Primary Sclerosing Cholangitis (PSC)

United States, Canada
Exact Sciences Corporation

Completed

Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer (DeeP-C)

Digestive System Diseases | Colonic Diseases | Colorectal Neoplasms | Colorectal Cancer

United States, Canada
Exact Sciences Corporation

Completed

Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing

Digestive System Diseases | Colonic Diseases | Colorectal Neoplasms | Colorectal Cancer

United States
Exact Sciences Corporation

Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Hepatitis B | Hepatocellular Carcinoma | Cirrhosis | Liver Cancer | Hepatocellular Cancer

United States
Exact Sciences Corporation

Completed

Home Usability Study of the SARS-CoV-2 (COVID-19) Test

COVID-19

United States
Exact Sciences Corporation

Completed

Stool Collection Sub-Study of Exact Sciences Protocol 2018-01

Cancer | Colorectal Cancer | Colo-rectal Cancer

United States
Exact Sciences Corporation

Completed

Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

Hepatocellular Carcinoma | Hepatocellular Carcinoma Surveillance

United States, Taiwan, Thailand, Germany, France, Spain, Italy
Exact Sciences Corporation

Terminated

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

Colorectal Cancer

United States
Exact Sciences Corporation

Completed

A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval

Colorectal Cancer | Colorectal Cancer Screening

United States
Exact Sciences Corporation

Completed

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Digestive System Diseases | Colonic Diseases | Colorectal Neoplasms | Colorectal Cancer

United States, Canada
UnicoCell Biomed CO. LTD
Protech Pharmaservices Corporation (PPC)

Completed

Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease

Moderate to Severe Chronic Kidney Disease

Taiwan
Posit Science Corporation

Active, not recruiting

Remote Digital Health Intervention to Improve Balance and Reduce Fall Risk (rSTAND)

Fall

United States
Posit Science Corporation

Withdrawn

Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD)

Parkinson's Disease
Posit Science Corporation

Completed

Computerized Attention Training for Individuals With Acquired Brain Injury

Stroke | Acquired Brain Injury | Hemispatial Neglect

United States
Posit Science Corporation

Completed

STATE Trial: SusTained Attention Training to Enhance Sleep - Remote (STATE)

Insomnia Chronic

United States
Posit Science Corporation

Completed

Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD) (MDD)

Major Depressive Disorder

United States
M's Science Corporation

Completed

SA4503 8-Week Study in Major Depressive Disorder (MDD)

Depressive Disorder, Major

Finland
Posit Science Corporation

Completed

Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment

Breast Cancer | Memory Disorders | Cognitive Symptoms

United States

3

Subscribe